Related Experiment Video

Updated: May 15, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

New treatment trends in small cell carcinoma of the urinary bladder

M A N Sendur, S Aksoy, O Yazici

    Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
    |January 22, 2013
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
    08:43

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

    Published on: July 28, 2012

    Related Experiment Videos

    Last Updated: May 15, 2026

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
    11:02

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

    Published on: October 30, 2013

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
    08:43

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

    Published on: July 28, 2012

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Urinary Tract Calculi VI: Surgical Management01:25

    Urinary Tract Calculi VI: Surgical Management

    Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...

    Articles linked to this work by shared authors, journal, and citation graph.

    Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure.

    Breast (Edinburgh, Scotland)·2026

    Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma.

    Frontiers in oncology·2025

    SYNCHRONOUS ONCOCYTIC CARCINOMA, MEDULLARY CARCINOMA AND PAPILLARY MICROCARCINOMA OF THYROID.

    Acta endocrinologica (Bucharest, Romania : 2005)·2025

    Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2025

    Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2025

    Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.

    Annals of oncology : official journal of the European Society for Medical Oncology·2024

    Vitamin C through upregulating SYNPO2 level suppresses the proliferation and migration of glioma cells.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2021

    Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2021

    Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in the treatment of rare tumors with peritoneal metastases.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2021

    COVID-19 vaccines and cancer patients: acceptance, attitudes and safety.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2021

    Assessment of oncology patients' satisfaction from intravenous chemotherapy.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2021

    The effect of adjuvant chemotherapy on the survival of patients with high-risk soft tissue sarcomas: Single center experience.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2021

    Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    IL-21 boosts T cell-therapy efficacy for solid tumors by enhancing mitochondrial Ca2+-mediated motility of effector CD8+ T cells.

    Cancer immunology research·2026

    Removal of boxed warning for menopausal hormone therapy: What nurses need to know.

    Nursing·2026

    Fruquintinib: Mechanism of Action, Clinical, and Translational Science.

    Clinical and translational science·2026

    The RNA-binding protein Psc1 functions downstream of the NDR/LATS kinase Cbk1 to modulate CO2 tolerance in Cryptococcus neoformans.

    mBio·2026

    In the wisdom of Odin: modular architecture, receptor trafficking and therapeutic implications.

    Expert opinion on therapeutic targets·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us